{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:56:10Z","timestamp":1790751370385,"version":"4.1.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7212097"],"award-info":[{"award-number":["No. 7212097"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dermatomyositis (DM) is associated with a substantially elevated risk of malignancy, yet the cutaneous features predictive of cancer risk in adults remain insufficiently defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to characterize cutaneous manifestations and clinical factors associated with malignancy in adult DM, with a focus on malignant erythema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 261 adults with DM admitted between 2016 and 2023 and followed up till June 2025. Clinical data, laboratory indicators (including creatine kinase [CK] and lactate dehydrogenase [LDH]), autoantibodies, and skin findings were systematically evaluated. The primary outcome was the occurrence of malignant tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty\u2011six patients (10%) developed malignancy. Malignant erythema was identified in 35 patients (13.3%), among whom 14 (40%) had malignancy. Both anti-transcription intermediary factor-1 \u03b3 (anti-TIF-1 \u03b3) antibodies and malignant erythema were independently associated with malignancy (odds ratio [OR] = 18.231, 95% confidence interval [CI] 4.568\u201372.756, P &amp;lt; 0.001; OR\u00a0=\u00a017.588, 95% CI 2.151\u2013143.824, P\u00a0=\u00a00.007). Malignant erythema demonstrated higher specificity for tumor prediction than anti-TIF-1 \u03b3 antibodies (91.1% vs. 86%, P &amp;lt; 0.001), while sensitivity did not differ significantly (53.8% vs. 73.1%, P\u00a0=\u00a00.190). while.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Malignant erythema is a distinctive poikilodermatous manifestation strongly associated with malignancy in adult DM. Its high specificity suggests that malignant erythema may serve as a valuable clinical indicator for malignancy risk and a useful complement to anti-TIF-1 \u03b3 antibody testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1960856","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:05:48Z","timestamp":1790748348000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Malignant erythema as a high-specificity cutaneous indicator of malignancy in adult dermatomyositis: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaojing","family":"Xing","sequence":"first","affiliation":[{"name":"Department of Dermatology, Capital Medical University Affiliated Beijing Shijitan Hospital","place":["Beijing, China"]},{"name":"Department of Dermatology, First Medical Centre of Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Medical Centre of Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biwen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Medical Centre of Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13075-024-03368-9","article-title":"Clinical relevance of positively determined myositis antibodies in rheumatology: a retrospective monocentric analysis","volume":"26","author":"Schumacher","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in dermatomyositis and polymyositis","volume":"21","author":"Qiang","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1038\/s41598-021-83729-5","article-title":"Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan","volume":"11","author":"Hsu","year":"2021","journal-title":"Sci Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3760\/cmaj.cn112137-20230329-00505","article-title":"Risk factors analysis and prediction model establishment of malignant tumor in patients with polymyositis\/dermatomyositis","volume":"103","author":"Wang","year":"2023","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04910-w","article-title":"Mortality of Chinese patients with polymyositis and dermatomyositis","volume":"39","author":"Yang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5841","article-title":"Risk-based screening for cancer in patients with dermatomyositis: Toward a more individualized approach","volume":"158","author":"Vaughan","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1503140","article-title":"Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3390\/medicina61111932","article-title":"Malignancy risk and predictors in dermatomyositis and polymyositis: a large population-based study","volume":"61","author":"Patt","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/wco.0000000000000376","article-title":"Advances in serological diagnostics of inflammatory myopathies","volume":"29","author":"Benveniste","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.41","article-title":"Association of anti-CCAR1 autoantibodies with decreased cancer risk relative to the general population in patients with anti-transcriptional intermediary factor 1\u03b3-positive dermatomyositis","volume":"75","author":"Fiorentino","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13256-021-02664-1","article-title":"Anti-transcription intermediary factor 1 gamma (TIF1\u03b3) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature","volume":"15","author":"Ono","year":"2021","journal-title":"J Med Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06751-0","article-title":"Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population","volume":"42","author":"Manwatkar","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14759","article-title":"Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients","volume":"32","author":"Best","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B17","author":"Chuang","year":"2001"},{"key":"B18","first-page":"122","author":"Fu","year":"2020"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez572","article-title":"Anti-TIF1-\u03b3 autoantibodies: warning lights of a tumour autoantigen","volume":"59","author":"De Vooght","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.148.3.6878708","article-title":"A method of comparing the areas under receiver operating characteristic curves derived from the same cases","volume":"148","author":"Hanley","year":"1983","journal-title":"Radiology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez238","article-title":"Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study","volume":"59","author":"Kaneko","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021733","article-title":"Malignancy in dermatomyositis: a retrospective paired case-control study of 202 patients from Central China","volume":"99","author":"Chang","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/clinpract15020031","article-title":"Clinical features of dermatomyositis associated with myositis-specific antibodies in Moroccan patients","volume":"15","author":"Chihi","year":"2025","journal-title":"Clin Pract"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04562-w","article-title":"Diffuse pruritic erythema as a clinical manifestation in anti-SAE antibody-associated dermatomyositis: a case report and literature review","volume":"38","author":"Jia","year":"2019","journal-title":"Clin Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1960856\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:05:49Z","timestamp":1790748349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1960856\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2026.1960856"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1960856","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1960856"}}